AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31699278 — intervention group
Group type: COMPARATOR
Intervention: Men with de novo heart failure at hospital presentation
Number of subjects: 10443
Study 31699278 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure
Number of subjects: 10443
Study 31699278 — intervention group
Group type: COMPARATOR
Intervention: Men with de novo heart failure
Number of subjects: 10443
Study 31699278 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure undergoing reperfusion therapy
Number of subjects: 10443
Study 31699278 — intervention group
Group type: COMPARATOR
Intervention: Men with de novo heart failure undergoing reperfusion therapy
Number of subjects: 10443
Study 31699696 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measured using the EuroQol five-dimension questionnaire at hospitalisation, 1, 6 and 12 months post-AMI.
Number of subjects: 9566
Study 31699696 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced HRQoL associated with various factors including gender and comorbidities.
Number of subjects: 9566
Study 31699696 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class growth analysis (LCGA) identified subgroups of HRQoL.
Number of subjects: 9566
Study 31699743 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 0
Study 31699743 — intervention group
Group type: COMPARATOR
Intervention: Status quo (no cash transfers)
Number of subjects: 0
Study 31699745 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese pregnant women (BMI ≥30 kg/m²)
Number of subjects: 188
Study 31699745 — intervention group
Group type: COMPARATOR
Intervention: Non-obese pregnant women
Number of subjects: 188
Study 31699827 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4573 (highly selective CDK9 inhibitor)
Number of subjects: 0
Study 31700871 — intervention group
Group type: EXPERIMENTAL
Intervention: JS001 at 10 mg/kg
Number of subjects: 20
Study 31700871 — intervention group
Group type: EXPERIMENTAL
Intervention: JS001 at 3 mg/kg
Number of subjects: 20
Study 31700871 — intervention group
Group type: EXPERIMENTAL
Intervention: JS001 (all doses)
Number of subjects: 20
Study 31700871 — intervention group
Group type: EXPERIMENTAL
Intervention: JS001 (PD-L1 positive subjects)
Number of subjects: 20
Study 31700924 — intervention group
Group type: EXPERIMENTAL
Intervention: Taodan granules (TDKL), administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216
Study 31700924 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216
Study 31700924 — intervention group
Group type: EXPERIMENTAL
Intervention: Taodan granules (TDKL) and Placebo, both administered twice per day, 7 days per week, for 8 weeks.
Number of subjects: 216
Study 31701043 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) dressing (PICO™, Smith & Nephew, UK)
Number of subjects: 491
Study 31701043 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 491
Study 31701169 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose reduced to cumulative 60 Gy with simultaneous chemotherapy regimen of cisplatin 30 mg/m²
Number of subjects: 0
Study 31701169 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal treatments
Number of subjects: 0
Study 31701294 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) Fidelity scale
Number of subjects: 0
Study 31701679 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect MM Registry
Number of subjects: 3011
Study 31701679 — intervention group
Group type: COMPARATOR
Intervention: SEER and NCDB databases
Number of subjects: 3011
Study 31702640 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture on the highest sensitized acupoints after 20 sessions
Number of subjects: 30
Study 31702640 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30
Study 31703570 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconsolidation Therapy (RT) - involves recalling traumatic events with propranolol, once a week for 10-25 minutes over 6 weeks
Number of subjects: 400
Study 31703570 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 400
Study 31703604 — intervention group
Group type: EXPERIMENTAL
Intervention: Domatinostat combined with pembrolizumab
Number of subjects: 0
Study 31703604 — intervention group
Group type: EXPERIMENTAL
Intervention: Domatinostat
Number of subjects: 0
Study 31703604 — intervention group
Group type: EXPERIMENTAL
Intervention: Domatinostat for 14 days in patients
Number of subjects: 0
Study 31703606 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tube clearance (Phase 2)
Number of subjects: 697
Study 31703628 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination of thrombus formation
Number of subjects: 30
Study 31703628 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescence method for factor VIII and fibrinogen
Number of subjects: 30
Study 31703628 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination of thrombus
Number of subjects: 30
Study 31703637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg followed by palliative radiotherapy with 5 × 4 Gray (Gy) = 20 Gy photon radiation (Group A)
Number of subjects: 130
Study 31703637 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (Group B)
Number of subjects: 130
Study 31703728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eribulin (1.4 mg/m² daily) and everolimus (5 mg daily) at dose level A1
Number of subjects: 27
Study 31703728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus at dose level A2
Number of subjects: 27
Study 31703728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus at dose level B1
Number of subjects: 27
Study 31703728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eribulin and everolimus
Number of subjects: 27
Study 31703971 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of RCC
Number of subjects: 1943
Study 31703971 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, pathological T3/4 stage, pathological N1/2 stage, Fuhrman grades 3 and 4
Number of subjects: 1943
Study 31704134 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on days 8 and 15 for cohorts 1 and 2.
Number of subjects: 532
Study 31704214 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-boosted lopinavir/ritonavir (LPV/r) 400/400 mg
Number of subjects: 0
Study 31704699 — intervention group
Group type: EXPERIMENTAL
Intervention: HMC group
Number of subjects: 94
Study 31704699 — intervention group
Group type: COMPARATOR
Intervention: ARC group
Number of subjects: 94
Study 31705425 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial substrate metabolism in BTHS
Number of subjects: 14
Study 31705425 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaffected individuals)
Number of subjects: 14
Study 31705521 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC Dipstick pads
Number of subjects: 914
Study 31705521 — intervention group
Group type: COMPARATOR
Intervention: Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Number of subjects: 914
Study 31705547 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira) starting dose of 16 units
Number of subjects: 0
Study 31705547 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 0
Study 31705547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31705738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical Skin Conductance (ESC) measured in microsiemens (µS) with Sudoscan
Number of subjects: 50
Study 31705738 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST) of cold and warm detection and pain thresholds
Number of subjects: 50
Study 31705738 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological, quality of life, sleep, and social characteristics assessments
Number of subjects: 50
Study 31705855 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPBANG score
Number of subjects: 248
Study 31705855 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Apnea Prediction Index (MAPI)
Number of subjects: 248
Study 31705855 — intervention group
Group type: COMPARATOR
Intervention: Berlin high-risk score
Number of subjects: 248
Study 31706057 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 226
Study 31706057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 226
Study 31706060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope
Number of subjects: 73
Study 31706060 — intervention group
Group type: COMPARATOR
Intervention: Single-use duodenoscope followed by crossover to reusable duodenoscope
Number of subjects: 73
Study 31706318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perceptions of their role in addressing childhood overweight/obesity
Number of subjects: 442
Study 31706318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perceptions of organizational barriers
Number of subjects: 442
Study 31706318 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improving care
Number of subjects: 442
Study 31706360 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing and oral care (SOC) intervention
Number of subjects: 171
Study 31706360 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 171
Study 31706582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 0
Study 31707159 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 105
Study 31707795 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin, dosage and duration not specified
Number of subjects: 0
Study 31707795 — intervention group
Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study 31707833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent thrombosis
Number of subjects: 0
Study 31707833 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31707942 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitative endovascular balloon occlusion of the aorta (REBOA) during cardiopulmonary resuscitation
Number of subjects: 0
Study 31707942 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cardiac life support
Number of subjects: 0
Study 31707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib, 20 mg orally twice daily for a 28-day cycle, continued for up to 16 cycles or until progressive disease or intolerability.
Number of subjects: 19
Study 31707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib in HL patients with JAK2 amplification.
Number of subjects: 19
Study 31707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib in PMBCL patients.
Number of subjects: 19
Study 31707980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain threshold in the neck (measured at four standardized points)
Number of subjects: 372
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg BID) with chemotherapy (Regimen 1, continuous dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (400 mg BID) with chemotherapy (Regimen 1, intermittent dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg BID) with weekly paclitaxel (Regimen 2, continuous dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg BID) with weekly paclitaxel (Regimen 2, intermittent dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg BID) with intraperitoneal chemotherapy (Regimen 3, continuous dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (400 mg BID) with intraperitoneal chemotherapy (Regimen 3, intermittent dosing)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (150 mg po BID) with chemotherapy (Regimens 1c, 2c, 2i, and 3c)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (250 mg po BID) with chemotherapy (Regimen 1i)
Number of subjects: 424
Study 31708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (300 mg po BID) with chemotherapy (Regimen 3i)
Number of subjects: 424
Study 31708167 — intervention group
Group type: COMPARATOR
Intervention: Comparison of continuous vs intermittent dosing of veliparib
Number of subjects: 424
Study 31708188 — intervention group
Group type: EXPERIMENTAL
Intervention: TriClip tricuspid valve repair system
Number of subjects: 85
Study 31708296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg for three courses)
Number of subjects: 114
Study 31708735 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted stair climbing training
Number of subjects: 32
Study 31708735 — intervention group
Group type: COMPARATOR
Intervention: Sensory integration balance training
Number of subjects: 32
Study 31708810 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCESS Integrated Care Model including Therapeutic Assertive Community Treatment
Number of subjects: 0
Study 31708812 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31708824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 0
Study 31708824 — intervention group
Group type: COMPARATOR
Intervention: Current physical activity
Number of subjects: 0
Study 31708824 — intervention group
Group type: COMPARATOR
Intervention: Brain-Derived Neurotrophic Factor (BDNF) levels
Number of subjects: 0
Study 31708890 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Ultraviolet B (NB-UVB) light exposure
Number of subjects: 0
Study 31709259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (800 IU daily for 6 months)
Number of subjects: 58
Study 31709259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31709648 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 786
Study 31709982 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing (automated, enhanced accelerometer-based algorithm)
Number of subjects: 75
Study 31709982 — intervention group
Group type: COMPARATOR
Intervention: VVI-50 pacing (control)
Number of subjects: 75
Study 31709982 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 75
Study 31710189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil (suppository-100 mg/daily)
Number of subjects: 66
Study 31710189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal placebo/sildenafil (suppository-100 mg/daily)
Number of subjects: 66
Study 31710189 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo (suppository)
Number of subjects: 66
Study 31710189 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 66
Study 31710193 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 60
Study 31710193 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 60
Study 31710528 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31710684 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype classification (gNMs-F, gNMs-S, gIMs, gPMs)
Number of subjects: 100
Study 31710684 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies and side effects experienced by patients
Number of subjects: 100
Study 31710684 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of metabolic activity
Number of subjects: 100
Study 31710793 — intervention group
Group type: COMPARATOR
Intervention: Proposed COPDGene criteria for diagnosing COPD
Number of subjects: 8784
Study 31710793 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded criteria for COPD diagnosis
Number of subjects: 8784
Study 31710793 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach using environmental exposure, clinical symptoms, CT imaging and spirometric criteria
Number of subjects: 8784
Study 31710864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 25
Study 31710859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Disorder Questionnaire (MDQ) screening for bipolar disorder
Number of subjects: 574
Study 31710859 — intervention group
Group type: EXPERIMENTAL
Intervention: Current psychiatric care
Number of subjects: 574
Study 31710876 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia and high rumination
Number of subjects: 267
Study 31710876 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia alone
Number of subjects: 267
Study 31710876 — intervention group
Group type: EXPERIMENTAL
Intervention: High rumination alone
Number of subjects: 267
Study 31710876 — intervention group
Group type: COMPARATOR
Intervention: Good-sleeping women with low rumination
Number of subjects: 267
Study 31710876 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed women
Number of subjects: 267
Study 31710876 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 267
Study 31711108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact casein (C)
Number of subjects: 0
Study 31711108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (HC)
Number of subjects: 0
Study 31711108 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amino acid mixture (A)
Number of subjects: 0
Study 31711111 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Wishes Project (3WP) intervention
Number of subjects: 730
Study 31711170 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumers (consumed breakfast ≥230 kcal between 04:00 and 10:00)
Number of subjects: 472
Study 31711170 — intervention group
Group type: COMPARATOR
Intervention: Breakfast skippers (did not consume breakfast ≥230 kcal)
Number of subjects: 472
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse (CAI) reported with ≥1 of their last three partners
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with casual partners in homes
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with casual partners in hotels
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with anonymous partners in saunas/Internet cabins
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with anonymous partners in public spaces
Number of subjects: 447
Study 31711433 — intervention group
Group type: COMPARATOR
Intervention: CAI in hotels compared to homes
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use before sex at home
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner alcohol use before sex in saunas/Internet cabins
Number of subjects: 447
Study 31711433 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner alcohol use before sex in public spaces
Number of subjects: 447
Study 31712075 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of pain with opioid analgesics
Number of subjects: 1612
Study 31712075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy at hospital admission
Number of subjects: 1612
Study 31712075 — intervention group
Group type: COMPARATOR
Intervention: Severe acute pancreatitis outcomes
Number of subjects: 1612
Study 31712075 — intervention group
Group type: COMPARATOR
Intervention: Etiology of acute pancreatitis
Number of subjects: 1612
Study 31712075 — intervention group
Group type: COMPARATOR
Intervention: Demographics and comorbid conditions
Number of subjects: 1612
Study 31712075 — intervention group
Group type: COMPARATOR
Intervention: Classification of disease severity
Number of subjects: 1612
Study 31712344 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital delay
Number of subjects: 7312
Study 31712344 — intervention group
Group type: EXPERIMENTAL
Intervention: First ECG delay
Number of subjects: 7312
Study 31712344 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy delay
Number of subjects: 7312
Study 31712344 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital delay
Number of subjects: 7312
Study 31712349 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplastic drugs (AD) exposure in nursing staff
Number of subjects: 0
Study 31712349 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-questionnaire detailing professional activities
Number of subjects: 0
Study 31712445 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC-associated microbiota
Number of subjects: 0
Study 31712445 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls' microbiota
Number of subjects: 0
Study 31712720 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) of panic disorder
Number of subjects: 2248
Study 31712720 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage disequilibrium (LD) score regression analysis
Number of subjects: 2248
Study 31712720 — intervention group
Group type: EXPERIMENTAL
Intervention: 255 single-nucleotide polymorphisms (SNPs)
Number of subjects: 2248
Study 31712813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 360 mg intramuscular dose
Number of subjects: 10
Study 31712813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin Cmax and MIC measurements
Number of subjects: 10
Study 31712813 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine measurement
Number of subjects: 10
Study 31712813 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache incidence
Number of subjects: 10
Study 31713013 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs
Number of subjects: 30
Study 31713013 — intervention group
Group type: COMPARATOR
Intervention: Routine ward rounds
Number of subjects: 30